NEW YORK, July 20, 2026
Nuvation Bio Inc. has announced positive updated Phase II clinical data for safusidenib, its investigational selective mutant IDH1 inhibitor, alongside a major expansion of its clinical development program with two new studies designed to broaden treatment options for patients with IDH1-mutant glioma. The updated long-term findings demonstrated a confirmed objective response rate (ORR) of 52% and a 36-month progression-free survival (PFS) rate of 79%, based on nearly 40 months of follow-up, reinforcing the therapy’s durable anti-tumor activity and manageable safety profile. Building on these encouraging results, the company will launch a global Phase III study in newly diagnosed grade 2 glioma patients outside the United States and a Phase II study evaluating safusidenib in patients whose disease has progressed after treatment with vorasidenib in the United States. The announcement strengthens Nuvation Bio’s commitment to advancing targeted therapies across the full spectrum of IDH1-mutant brain cancers.
Updated Phase II Results Show Durable Clinical Benefit
The latest data from the Phase II J201 study, involving patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant glioma, demonstrated sustained and deepening clinical responses after extended follow-up. At a median follow-up of 38.8 months, investigators reported a centrally assessed confirmed ORR of 51.9%, while the median progression-free survival had not yet been reached. The estimated 36-month PFS rate reached 79.1%, highlighting the durability of disease control achieved with safusidenib. Importantly, only one previously responding patient experienced disease progression during long-term observation, and no new safety signals were identified, supporting the therapy’s favorable risk-benefit profile. These findings further validate safusidenib as a promising targeted therapy for patients with low-grade IDH1-mutant glioma, where effective long-term treatment options remain limited.
Two New Clinical Studies Broaden Development Strategy
Supported by the positive Phase II findings, Nuvation Bio is significantly expanding the clinical evaluation of safusidenib through two additional studies targeting distinct patient populations. The new Phase III G307 trial will enroll approximately 140 newly diagnosed grade 2 IDH1-mutant glioma patients outside the United States who have not yet received chemotherapy or radiation, particularly in regions where vorasidenib is not yet available. Simultaneously, the Phase II G209 study will recruit up to 40 patients in the United States with grade 2 or grade 3 IDH1-mutant glioma whose disease has progressed following prior treatment with vorasidenib. This study aims to evaluate whether safusidenib can provide an additional targeted treatment option capable of delaying chemotherapy or radiation therapy in patients with limited alternatives. Together, these trials expand the investigational program to address multiple stages of IDH1-mutant glioma, supporting a comprehensive development strategy.
Advertisement
Targeted Therapy Advances Precision Neuro-Oncology
IDH1-mutant glioma represents one of the most common molecular subtypes of adult brain cancer, affecting thousands of patients worldwide each year. Although targeted therapies have transformed disease management, important treatment gaps remain, particularly after progression on first-line targeted inhibitors. Safusidenib is an investigational, brain-penetrant oral inhibitor of mutant IDH1 designed to selectively block tumor-driving mutations while demonstrating durable anti-tumor activity and an encouraging safety profile. The expanded development program complements the ongoing Phase III SIGMA study, which is evaluating safusidenib as maintenance therapy following standard-of-care treatment in patients with high-risk IDH1-mutant astrocytoma. By advancing multiple late-stage clinical studies across different disease settings, Nuvation Bio aims to establish safusidenib as a comprehensive treatment option capable of addressing significant unmet medical needs throughout the IDH1-mutant glioma treatment landscape.
Source: Nuvation Bio press release
